An early study showed that bone marrow cells might protect the CML cell lines K562 and KU812 from imatinib treatment, perhaps due to the activation of Stat5-mediated NF-κB signaling upon an interaction between bone marrow stroma and CML cells [132]. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.